{'52WeekChange': 0.23369169,
 'SandP52WeekChange': 0.0644362,
 'address1': '800 Saginaw Drive',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 18.05,
 'askSize': 3100,
 'averageDailyVolume10Day': 958550,
 'averageVolume': 1327766,
 'averageVolume10days': 958550,
 'beta': 2.185994,
 'beta3Year': None,
 'bid': 14.25,
 'bidSize': 1200,
 'bookValue': 3.805,
 'category': None,
 'circulatingSupply': None,
 'city': 'Redwood City',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 17.49,
 'dayLow': 16.6,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -14.911,
 'enterpriseToRevenue': 4466.394,
 'enterpriseValue': 1116598528,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '650-649-1995',
 'fiftyDayAverage': 21.083857,
 'fiftyTwoWeekHigh': 26.98,
 'fiftyTwoWeekLow': 4.96,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 51414050,
 'forwardEps': -1.28,
 'forwardPE': -13.4453125,
 'fromCurrency': None,
 'fullTimeEmployees': 114,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.03342,
 'heldPercentInstitutions': 0.80011004,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/adverum.com',
 'longBusinessSummary': 'Adverum Biotechnologies, Inc., a clinical-stage gene '
                        'therapy company, engages in developing gene therapy '
                        'product candidates to treat ocular and rare diseases. '
                        'Its pipeline of product candidates includes ADVM-022, '
                        'an adeno- associated virus (AAV). 7m8-aflibercept for '
                        'the treatment of wet age-related macular '
                        'degeneration; ADVM-043, an investigational gene '
                        'therapy candidate for the treatment of alpha-1 '
                        'antitrypsin deficiency; and ADVM-053, a preclinical '
                        'gene therapy product candidate for the treatment of '
                        'hereditary angioedema. The company has collaboration '
                        'agreements with Editas Medicine, Inc. to leverage its '
                        'proprietary AAV vectors for genome editing '
                        'technologies to treat up to five inherited retinal '
                        'diseases; and Regeneron Pharmaceuticals, Inc. for the '
                        'development of up to eight distinct ocular '
                        'therapeutic targets. The company was formerly known '
                        'as Avalanche Biotechnologies, Inc. and changed its '
                        'name to Adverum Biotechnologies, Inc. in May 2016. '
                        'Adverum Biotechnologies, Inc. was founded in 2006 and '
                        'is headquartered in Redwood City, California.',
 'longName': 'Adverum Biotechnologies, Inc.',
 'market': 'us_market',
 'marketCap': 1381887232,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_207074711',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -72903000,
 'nextFiscalYearEnd': 1640908800,
 'open': 17.2,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '650-656-9323',
 'previousClose': 17.27,
 'priceHint': 2,
 'priceToBook': 4.522996,
 'priceToSalesTrailing12Months': 5527.549,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 17.49,
 'regularMarketDayLow': 16.6,
 'regularMarketOpen': 17.2,
 'regularMarketPreviousClose': 17.27,
 'regularMarketPrice': 17.2,
 'regularMarketVolume': 737539,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 80295600,
 'sharesPercentSharesOut': 0.1361,
 'sharesShort': 10929575,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 11842812,
 'shortName': 'Adverum Biotechnologies, Inc.',
 'shortPercentOfFloat': 0.1504,
 'shortRatio': 8.03,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'ADVM',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.092,
 'twoHundredDayAverage': 15.29687,
 'volume': 737539,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.adverum.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94063'}